Mainland China funds increase stakes in Hong Kong biotech amid surge of licensing deals

Analysts say valuation of the sector is attractive, with biotech firms trading relatively cheaply

Opens the original publisher in a new tab. Full articles belong to their publishers; a subscription may be required.